Lab
Firstpath Laboratory Services LLC
Firstpath Laboratory Services LLC was paid $174K by Medicaid between Apr 2018 and Apr 2024, across 55 billing codes. Its largest line is 88377, — 36% of everything it billed.
33Billing provider infoFIRSTPATH LABORATORY SERVICES LLC
POMPANO BEACH, FL 33069
POMPANO BEACH, FL 33069
33aNPI1215170774assigned 04/14/2009
33bProvider typeClinical Medical Laboratory
28Total paid$174K
24GClaims28,628
24DCodes billed55
24AFirst – last monthApr 2018 – Apr 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#85 of 225
Median peer was paid$74K
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 388 | $247.54 | |
| 2019 | 2,276 | $6K | |
| 2020 | 1,518 | $304.62 | |
| 2021 | 515 | $14K | |
| 2022 | 2,680 | $21K | |
| 2023 | 16,585 | $81K | |
| 2024incomplete | 4,666 | $52K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88377 | 36% | 1,403 | 493 | $63K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 21% | 7,706 | 548 | $36K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 18% | 690 | 507 | $31K |
| 87481 | 4.3% | 1,805 | 382 | $7K | |
| 87529 | 2.9% | 1,197 | 490 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.7% | 270 | 188 | $5K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.7% | 111 | 61 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.7% | 640 | 456 | $3K |
| 87563 | 1.7% | 623 | 509 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 590 | 475 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.0% | 588 | 475 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 575 | 463 | $2K |
43 more codes
| 88142 | <1% | 762 | $2K | |
| 88141 | <1% | 585 | $2K | |
| 87653 | <1% | 459 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 216 | $1K |
| 87511 | <1% | 398 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,365 | $1K |
| 87900 | <1% | 72 | $261.01 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $247.62 |
| 88312 | <1% | 23 | $234.60 | |
| 87640 | <1% | 71 | $172.70 | |
| 80061 | Lipid panel | <1% | 839 | $155.36 |
| 80050 | General health panel | <1% | 561 | $148.24 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 62 | $142.80 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,478 | $130.87 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 597 | $107.40 |
| 82728 | <1% | 201 | $72.62 | |
| 83550 | <1% | 222 | $60.49 | |
| 87500 | <1% | 192 | $58.00 | |
| 82607 | <1% | 488 | $46.33 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 325 | $22.38 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 61 | $19.42 |
| 84439 | <1% | 273 | $17.39 | |
| 82270 | <1% | 42 | $14.65 | |
| 83540 | <1% | 223 | $13.18 | |
| 84403 | <1% | 15 | $12.11 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 795 | $10.57 |
| 0853T | <1% | 116 | $0.06 | |
| 0831T | <1% | 58 | $0.03 | |
| 83880 | 0% | 281 | $0.00 | |
| 82746 | 0% | 34 | $0.00 | |
| 83735 | 0% | 239 | $0.00 | |
| 81001 | 0% | 135 | $0.00 | |
| 87486 | 0% | 41 | $0.00 | |
| 87498 | 0% | 17 | $0.00 | |
| 87088 | 0% | 27 | $0.00 | |
| 87581 | 0% | 41 | $0.00 | |
| 87541 | 0% | 41 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 34 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 611 | $0.00 |
| 88120 | 0% | 33 | $0.00 | |
| 0500T | 0% | 279 | $0.00 | |
| 84481 | 0% | 83 | $0.00 | |
| 88104 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialINGRAM, MARC (CEO)
| Provider | Location | Paid |
|---|---|---|
| Convergent Diagnostics, LLC | Allen, TX | $3.18M |
| Knoxville Dermatopathology Laboratory LLC | Plano, TX | $942K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.